Targeting the Wnt pathway in zebrafish as a screening method to identify novel therapeutic compounds
- Authors
- Robertson, J.K., Danzmann, K., Charles, S., Blake, K., Olivares, A., Bamikole, S., Olson, M., and Raay, T.J.
- ID
- ZDB-PUB-140317-27
- Date
- 2014
- Source
- Experimental Biology and Medicine 239(2): 169-176 (Journal)
- Registered Authors
- Keywords
- Cancer, LiCl, Wnt signaling, eyeless, small molecules, zebrafish
- MeSH Terms
-
- Animals
- Colorectal Neoplasms/drug therapy
- Colorectal Neoplasms/genetics
- Colorectal Neoplasms/metabolism
- Drug Evaluation, Preclinical/methods*
- Embryo, Nonmammalian/drug effects
- Embryonic Development/drug effects
- Embryonic Development/genetics
- Gene Expression Regulation, Developmental/drug effects
- Glycogen Synthase Kinase 3/antagonists & inhibitors
- Heterocyclic Compounds, 3-Ring/pharmacology
- Lithium Chloride/pharmacology
- Phenotype
- Wnt Signaling Pathway/drug effects*
- Zebrafish/embryology
- Zebrafish/metabolism*
- PubMed
- 24414478 Full text @ Exp. Biol. Med.
Activating mutations in the Wnt signaling pathway account for the initiation of greater than 90% of all colorectal cancers and this pathway has been implicated in numerous other diseases. Therefore, identifying small molecule inhibitors of this pathway is of critical importance towards identifying clinically relevant drugs. Numerous screens have been employed to identify therapeutic reagents, but none have made it to advanced clinical trials, suggesting that traditional screening methods are ineffective at identifying clinically relevant targets. Here, we describe a novel in vivo screen to identify small molecule inhibitors of the Wnt pathway. Specifically, treatment of zebrafish embryos with LiCl inhibits GSK3 kinase function, resulting in hyperactivation of the signaling pathway and an eyeless phenotype at 1 day post fertilization. Using the small molecule XAV939, a known inhibitor of Wnt signaling, we rescued the LiCl induced eyeless phenotype, confirming efficacy of the screen. We next tested our assay with 400 known small molecule kinase inhibitors, none of which should inhibit Wnt signaling below the level of GSK3 based on their known targets. Accordingly, none of these small molecules rescued the eyeless phenotype, which demonstrates the stringency of the assay. However, several of these small molecule kinase inhibitors did generate a non-Wnt phenotype in accordance with the kinase they targeted. Therefore, combining the efficacy, sensitivity, and stringency of this preliminary screen, this model will provide an alternative to the traditional in vitro screen, generating potentially clinical relevant drugs in a rapid and cost-effective way.